Download PDF
Thromb Haemost 2012; 107(06): 1180-1182
DOI: 10.1160/TH11-12-0851
Letters to the Editor
Schattauer GmbH

Effects of atorvastatin on plasma fibrin clot properties in apparently healthy individuals and patients with previous venous thromboembolism

Marek Zolcinski
1   John Paul II Hospital, Krakow, Poland
,
Mariola Ciesla-Dul
1   John Paul II Hospital, Krakow, Poland
,
Anetta Undas
1   John Paul II Hospital, Krakow, Poland
2   Institute of Cardiology, Jagiellonian University Medical College, Krakow, Poland
› Author Affiliations
Further Information

Publication History

Received: 10 December 2011

Accepted after minor revision: 27 January 2012

Publication Date:
29 November 2017 (online)

    Permissions and Reprints

 

 

  • References

  • 1 Undas A, Ariëns RA. Fibrin clot structure and function: A role in the pathophysiology of arterial and venous thromboembolic diseases. Arterioscler Thromb Vasc Biol 2011; 31: e88-99.
    CrossrefPubMedGoogle Scholar
  • 2 Undas A. Acquired dysfibrinogenemia in atherosclerotic vascular disease. Pol Arch Med Wewn 2011; 121: 310-319.
    PubMedGoogle Scholar
  • 3 Undas A, Zawilska K, Ciesla-Dul M. et al. Altered fibrin clot structure/function in patients with idiopathic venous thromboembolism and in their relatives. Blood 2009; 114: 4272-4278.
    CrossrefPubMedGoogle Scholar
  • 4 Undas A, Brummel-Ziedins KE, Mann KG. Statins and blood coagulation. Arterioscler Thromb Vasc Biol 2005; 25: 287-294.
    PubMedGoogle Scholar
  • 5 Zhou Q, Liao JK. Statins and cardiovascular diseases: From cholesterol lowering to pleiotropy. Curr Pharm Des 2009; 15: 467-478.
    CrossrefPubMedGoogle Scholar
  • 6 Undas A, Celinska-Löwenhoff M, Löwenhoff T. et al. Statins, fenofibrate, and quinapril increase clot permeability and enhance fibrinolysis in patients with coronary artery disease. J Thromb Haemost 2006; 4: 1029-1036.
    CrossrefPubMedGoogle Scholar
  • 7 Undas A, Plicner D, Stepien E. et al. Altered fibrin clot structure in patients with advanced coronary artery disease: a role of C-reactive protein, lipoprotein(a), and homocysteine. J Thromb Haemost 2007; 5: 1988-1990.
    CrossrefPubMedGoogle Scholar
  • 8 Undas A, Topór-Madry R, Tracz W. Simvastatin increases clot permeability and susceptibility to lysis in patients with LDL cholesterol below 3.4 mmol/l. Pol Arch Med Wewn 2009; 119: 354-359.
    PubMedGoogle Scholar
  • 9 Squizzato A, Galli M, Romualdi E. et al. Statins, fibrates, and venous thromboembolism: A metaanalysis. Eur Heart J 2010; 31: 1248-1256.
    CrossrefPubMedGoogle Scholar
  • 10 Glynn R, Danielson E, Fonseca F. et al. A randomized trial of rosuvastatin in the prevention of venous thromboembolism. N Engl J Med 2009; 360: 1851-1861.
    CrossrefPubMedGoogle Scholar
  • 11 Lisman T, de Groot PG, Meijers JC, Rosendaal FR. Reduced plasma fibrinolytic potential is a risk factor for venous thrombosis. Blood 2005; 105: 1102-1105.
    CrossrefPubMedGoogle Scholar
  • 12 Cosmi B, Legnani C, Cini M. et al. D-dimer and residual vein obstruction as risk factors for recurrence during and after anticoagulation withdrawal in patients with a first episode of provoked deep-vein thrombosis. Thromb Haemost 2011; 105: 837-845.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 13 Hoffman M. Alterations of fibrinogen structure in human disease. Cardiovasc Hematol Agents Med Chem 2008; 6: 206-211.
    CrossrefPubMedGoogle Scholar